Neovacs announced the successful in vivo proof of concept testing of its IL-4 /IL1-3 Kinoid therapeutic vaccine to treat respiratory allergies, in collaboration with a research team from the Institut Pasteur. The IL-4 /IL-13 Kinoid, a therapeutic vaccine from Neovacs' innovative technology is designed to target allergic diseases such as asthma and food allergies. The results obtained in this preclinical study show that the vaccine is able to inhibit bronchoconstriction, and therefore to restore breathing capacity.